Form 6-K Adaptimmune Therapeutics For: Nov 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Adaptimmune Therapeutics (ADAP) Narrows Q1 Loss
November 13, 2015 8:00 AM ESTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $-0.00, versus (GBP0.01) reported last year. Revenue for the quarter came in at GBP2.6 million, versus GBP944 thousand reported last year.
Adaptimmune is reiterating its cash burn guidance. For the six months ending December... More
